| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITRM | Ordinary Shares | Options Exercise | +1,197 | +42% | 4,030 | 01 Jan 2023 | Direct | F1, F2 | ||
| holding | ITRM | Ordinary Shares | 71,445 | 01 Jan 2023 | By New Leaf Ventures III, L.P. | F2, F3 | |||||
| holding | ITRM | Ordinary Shares | 25,641 | 01 Jan 2023 | By New Leaf Biopharma Opportunities II, L.P. | F2, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITRM | Restricted Share Units | Options Exercise | $0 | -1,197 | -100% | $0* | 0 | 01 Jan 2023 | Ordinary Shares | 1,197 | $0 | Direct | F1, F5, F6 |
| Id | Content |
|---|---|
| F1 | Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. |
| F2 | On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split. |
| F3 | These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any. |
| F4 | These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any. |
| F5 | On March 25, 2022, the reporting person was granted an award of 17,955 RSUs (the "RSU Grant"), which vested on January 1, 2023. |
| F6 | The number of ordinary shares underlying the RSU Grant have been adjusted to reflect the Reverse Share Split. |